Dr. Safferstein joined the PLSG in 2007. He served as Vice President, Business Development, Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products. Prior to joining Omrix, he was Executive Vice President, Corporate Development for TransPharma Medical, a privately-held medical device company.
From 2001 to 2005, Dr. Safferstein was Vice President, Business Development for Acorda Therapeutics, a CNS drug development and marketing company. Prior to joining Acorda Therapeutics, Dr. Safferstein served in various business development and marketing positions with Bristol-Myers Squibb. From 1991-1997, he was Director, Technology Transfer at the National Heart, Lung and Blood Institute and Cooperative Venture Manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Safferstein was an NIH Post-Doctoral Fellow and Fellow of the Multiple Sclerosis Society.
He received a B.A. in Biochemistry from Rutgers University, a Ph.D. in Human Anatomy and Neurobiology from the University of Louisville, a J.D. from the American University, Washington College of Law and an M.B.A. from Columbia University.
B.A. in Biochemistry, Rutgers University
PhD, Human Anatomy and Neurobiology, University of Louisville
JD, American University Washington College of Law
MBA, Columbia University